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Background: UC-II contains a patented form of undenatured type II collagen derived from chicken sternum.
Previous preclinical and clinical studies support the safety and efficacy of UC-II in modulating joint discomfort in
osteoarthritis and rheumatoid arthritis. The purpose of this study was to assess the efficacy and tolerability of UC-II
in moderating joint function and joint pain due to strenuous exercise in healthy subjects.
Methods: This randomized, double-blind, placebo-controlled study was conducted in healthy subjects who had no
prior history of arthritic disease or joint pain at rest but experienced joint discomfort with physical activity. Fifty-five
subjects who reported knee pain after participating in a standardized stepmill performance test were randomized
to receive placebo (n = 28) or the UC-II (40 mg daily, n = 27) product for 120 days. Joint function was assessed by
changes in degree of knee flexion and knee extension as well as measuring the time to experiencing and
recovering from joint pain following strenuous stepmill exertion.
Results: After 120 days of supplementation, subjects in the UC-II group exhibited a statistically significant
improvement in average knee extension compared to placebo (81.0 ± 1.3º vs 74.0 ± 2.2º; p = 0.011) and to baseline
(81.0 ± 1.3º vs 73.2 ± 1.9º; p = 0.002). The UC-II cohort also demonstrated a statistically significant change in average
knee extension at day 90 (78.8 ± 1.9º vs 73.2 ± 1.9º; p = 0.045) versus baseline. No significant change in knee
extension was observed in the placebo group at any time. It was also noted that the UC-II group exercised longer
before experiencing any initial joint discomfort at day 120 (2.8 ± 0.5 min, p = 0.019), compared to baseline
(1.4 ± 0.2 min). By contrast, no significant changes were seen in the placebo group. No product related adverse
events were observed during the study. At study conclusion, five individuals in the UC-II cohort reported no pain
during or after the stepmill protocol (p = 0.031, within visit) as compared to one subject in the placebo group.
Conclusions: Daily supplementation with 40 mg of UC-II was well tolerated and led to improved knee joint
extension in healthy subjects. UC-II also demonstrated the potential to lengthen the period of pain free strenuous
exertion and alleviate the joint pain that occasionally arises from such activities.
Keywords: UC-II, Undenatured type II collagen, Joint function, Knee extension, Stepmill, Joint pain* Correspondence: jay.udani@medicusresearch.com
2Medicus Research LLC, 28720 Roadside Drive, Suite 310, Agoura Hills, CA
91301, USA
4Northridge Hospital Integrative Medicine Program, Northridge, CA 91325,
USA
Full list of author information is available at the end of the article
© 2013 Lugo et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lugo et al. Journal of the International Society of Sports Nutrition 2013, 10:48 Page 2 of 12
http://www.jissn.com/content/10/1/48Introduction
The impact of strenuous exercise on knee joints may
cause localized pain and stiffness, which are hallmark
features of pathologic inflammatory disease [1]. It has
been shown that when dogs undergo a strenuous run-
ning regimen, significant losses in articular cartilage and
glycosaminoglycans occur [2]. Such studies suggest that
strenuous exercise may activate some of the same
physiological processes that occur in arthritic disease
[2-4]. In fact, in vitro studies have shown that many of
the cytokines implicated in the onset and progression of
both rheumatoid arthritis (RA) and osteoarthritis (OA)
also appear to regulate the remodeling of the normal
knee extracellular matrix (ECM) following strenuous
exertion [5].
When normal chondrocytes undergo strenuous mechan-
ical stimulation under static conditions, their physiology
shifts towards ECM breakdown, as indicated by the up-
regulation of several metalloproteinases (MMPs), such as
MMP-13 as well as tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1β, IL-6, and various aggrecanases [5,6]. This
in vitro catabolic response is mediated by changes in the
phosphorylation, expression, or translocation of several
transcription factors to the cell nucleus such as NF-κB,
p38 MAPK, Akt, and ERK [7,8]. By contrast, normal
chondrocytes produce the anti-inflammatory cytokine IL-4
when mechanically stimulated under moderate and dy-
namic conditions [9]. The secretion of this autocrine mol-
ecule not only helps in shifting chondrocyte metabolism
towards the synthesis of aggrecan and type II collagen, it
also downregulates production of nitric oxide (NO) and
various MMPs and aggrecanases [10-12]. This conclusion
is corroborated by the finding that pretreatment of
strenuously compressed normal chondrocytes with IL-4
attenuates their catabolic response [11]. This suggests
that IL-4 plays a key role in downregulating remodeling
functions, restoring articular cartilage homeostasis, as
well as decreasing chondrocyte apoptosis following
strenuous mechanical loading [12,13].
Mechanically stressed chondrocytes also produce a
number of other molecules known to participate in in-
flammatory responses, including prostoglandin E2, NO,
and vascular endothelial growth factor [14]. These are
proinflammatory molecules that, in conjunction with
TNF-α, IL-6 and IL-1β, result in a localized, and transi-
tory inflammatory-like response that is part of the nor-
mal repair process occurring in knee joints, serves to
moderate remodeling events [3]. Ostrowski et al. [15]
showed that healthy individuals express up to 27-fold
greater concentrations of the anti-inflammatory cytokine
IL-10 in blood following a marathon run when com-
pared to IL-10 blood levels at rest. This finding is not
surprising given that these same individuals also show
marked increases in the proinflammatory cytokinesTNF-α, IL-1β, and IL-6. It therefore appears that in
healthy subjects undergoing strenuous exertion, the in-
duction of proinflammatory cytokines is offset by the
synthesis of anti-inflammatory agents as part of the re-
covery process. This view is supported by the observa-
tion that IL-10 reduces the catabolic impact of IL-1β
and TNF-α on cartilage explants from healthy volun-
teers, and this effect is enhanced by combining IL-10
with IL-4 [13].
Another protein released by dynamically compressed
chondrocytes is transforming growth factor (TGF)-β
[16-18]. This factor is secreted by many cell types and is
known to interfere with the cell cycle and arrest differenti-
ation [19]. With regard to chondrocytes, TGF-β induces cell
proliferation in vitro and slows terminal differentiation into
hypertrophic cells [20]. Numerous studies have shown that
TGF-β reverses the in vitro catabolic effect of various
proinflammatory cytokines on normal chondrocytes as well
as chondrocytes harvested from RA and OA donors
[21-23].
The overall findings discussed above point to a new, uni-
fying view of joint physiology. It suggests that many of the
biological processes occurring in knee joints affected by RA
and OA also participate in the maintenance of healthy
knees [1,4,5]. It therefore seems appropriate to test the effi-
cacy of natural supplements or ingredients, which have
been shown to moderate joint pain in RA and OA, as
possible candidates for treating the joint discomfort that
occasionally results from strenuous exercise in healthy
individuals.
UC-II is a natural ingredient which contains a
glycosylated, undenatured type-II collagen [24]. Previous
studies have shown that small doses of UC-II modulate
joint health in both OA and RA [24-26]. Tong et al. [27],
using an in vivo model of collagen induced arthritis (CIA),
demonstrated that ingesting microgram quantities of
undenatured type II collagen significantly reduces circulat-
ing levels of inflammatory cytokines, potentially serving to
decrease both the incidence and the severity of arthritis
[28]. The ability to alter immunity via the ingestion of a
food, or an antigen, is called oral tolerance. This is an on-
going normal physiological process that protects the ali-
mentary tract against untoward immunological damage
[29,30]. Research into its mechanism of action has revealed
that several distinct types of T regulator cells mediate this
phenomenon by releasing IL-10 and TGF-β [30]. It has
also been shown that this effect is transitory in nature
requiring that the food, or antigen, be consumed con-
tinuously in order to maintain the tolerogenic state
[30]. Given these findings, plus our current understand-
ing of the role of various cytokines in normal joint
physiology, it was hypothesized that supplementation
with UC-II might relieve joint discomfort and restore
joint function in healthy subjects.
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controlled study was to assess the impact of UC-II on
knee function in otherwise healthy subjects with no
prior history of arthritic disease who experienced knee
pain upon strenuous physical exertion. The primary effi-
cacy variable for assessing knee function included mea-




The investigational study product UC-II is derived from
chicken sternum. It is manufactured using a patented, low-
temperature process to preserve its native structure. For
the clinical study, 40 mg of UC-II material (Lot 1109006),
which provides 10.4 ± 1.3 mg of native type-II collagen, was
encapsulated in an opaque capsule with excipients. Placebo
was dispensed in an identical capsule containing only excip-
ients (microcrystalline cellulose, magnesium stearate and
silicon dioxide). Both study materials were prepared in a
good manufacturing practice (GMP)-certified facility and
provided by InterHealth Nutraceuticals, Inc. (Benicia, CA).
Subjects were instructed to take one capsule daily with
water before bedtime.
Recruitment of subjects
One hundred and six subjects were screened for eligibil-
ity using the inclusion–exclusion criteria defined in
Table 1. Only healthy adults who presented with no knee
joint pain at rest and no diagnosable markers indicative
of active arthritic disease, as outlined by the American
College of Rheumatology (ACR) guidelines [31,32],
were admitted into the study. To accomplish this, all
potential subjects were screened by a board certified
clinician. Subjects presenting with any knee pain at
rest and at least 3 of 6 clinical classification criteria,
which included age greater than 50 years, morning
stiffness in the joint lasting 30 minutes or less, crepi-
tus on knee joint manipulation, body tenderness, bony
enlargements, knee swelling or presence of excess
fluid, and palpable warmth, were excluded. Potential
subjects reporting the occasional use of NSAIDs, other
pain relief medication, or anti-inflammatory supple-
ments underwent a 2-week washout period before
randomization.
Subjects were required to undergo a 10 minute period
of performance testing using a standardized stepmill test
developed and validated by Medicus Research (Udani JK,
unpublished observation). It involved exercising at level
4 on a StepMill® model 7000PT (StairMaster® Health &
Fitness Products, Inc., Kirkland, WA) until one or both
knees achieved a discomfort level of 5 on an 11 point
(0–10) Likert scale [33]. This pain threshold had to be
achieved within a 10 minute period otherwise thesubject was excluded. Once the requisite pain level was
achieved the subject was asked to continue stepping for
an additional two minutes in order to record the max-
imum pain level achieved before disembarking from the
stepmill. The following knee discomfort measures were
recorded from the start of the stepmill test: (1) time to
onset of initial joint pain; (2) time to onset of maximum
joint pain; (3) time to initial improvement in knee joint
pain; (4) time to complete recovery from knee joint pain.
Subjects who experienced a pain score of 5 (or greater)
within one minute of starting the stress test were ex-
cluded. Out of 106 screened candidates, 55 subjects were
enrolled in the study. Each subject voluntarily signed the
IRB-approved informed consent form. After enrollment,
the subjects were randomly assigned to either the pla-
cebo or the UC-II group.
Study design and trial site
This randomized, double blind, placebo-controlled study
was conducted at the Staywell Research clinical site lo-
cated in Northridge, CA. Medicus Research (Agoura
Hills, CA) was the contract research organization (CRO)
of record. The study protocol was approved by Coperni-
cus Group IRB (Cary, NC) on April 25th 2012. The
study followed the principles outlined in the Declaration
of Helsinki (version 1996).
Randomization and blinding
Simple randomization was employed using a software al-
gorithm based on the atmospheric noise method (www.
random.org). Sequential assignment was used to deter-
mine group allocation. Once allocated, the assignment
was documented and placed in individually numbered
envelopes to maintain blinding. Subjects, clinical staff,
plus data analysis and management staff remained
blinded throughout the study.
Study schedule
The study duration was 17 weeks with a total of 7 visits
that included screening, baseline, days 7, 30, 60, 90 and
120 (final visit). Table 2 summarizes the study visits and
activities. Figure 1 depicts the sequence of study proce-
dures that subjects underwent during each visit. All sub-
jects completed a medical history questionnaire at
baseline and compliance reports during follow-up evalu-
ations at 7, 30, 60, 90 and 120 days. Subjects were
assessed for anthropometric measures, vital signs, knee
range of motion (flexion and extension), six-minute
timed walk, as well as the onset and recovery from pain
using the Udani Stepmill Procedure. A Fitbit (San
Francisco, CA) device was used to measure daily dis-
tance walked, steps taken and an average step length for
study participants. Subjects were also asked to complete
the KOOS survey as well as the Stanford exercise scales.
Table 1 Inclusion–exclusion criteria
Inclusion
• Subject must be ≥30 and ≤65 years of age
• Body mass index (BMI) must be ≥18 and ≤35 kg/m2
• Knee joint criteria: (1) no knee joint discomfort at rest; (2) must
achieve a knee joint discomfort score of at least 5 on an 11-point
Likert scale within 10 minutes of initiating the stepmill protocol
• Maintain existing food and physical activity patterns throughout the
study period
• Judged by Investigator to be in general good health on the basis of
medical history
• Subject understands the study procedures and provides signed
informed consent to participate in the study and authorizes the
release of relevant health information to the study investigator
• Females of child bearing age must agree to use approved birth
control methods during the study
Exclusion
• Subjects with any indicators of arthritis, joint disorders, or history of
immune system or autoimmune disorders
• Daily use of NSAIDs; however, daily use of 81 mg of aspirin for
cardioprotection is allowed
• Daily use of anti-inflammatory or omega-3-fatty acid dietary
supplements or using supplements to maintain joint health 30 days
prior to screening
• Subjects with a history of knee or hip joint replacement surgery, or
any hip or back pain which interferes with ambulation
• Use of any immunosuppressive drugs in the last 12 months
(including steroids or biologics)
• Glucocorticoid injection or hyaluronic acid injection in affected knee
within 3 months prior to enrollment
• History of surgery or significant injury to the target joint within
6 months prior to study enrollment, or an anticipated need for
surgical or invasive procedure that will be performed during the
study
• Subjects with a chronic pain syndrome and in the judgment of the
Investigator is unlikely to respond to any therapy
• Participation in a clinical study with exposure to any non-registered
drug product within 30 days prior
• Subjects who have any physical disability which could interfere with
their ability to perform the functional performance measures
included in this protocol
• Any significant GI condition that would potentially interfere with the
evaluation of the study product
• Clinically significant renal, hepatic, endocrine (including diabetes
mellitus), cardiac, pulmonary, pancreatic, neurologic, hematologic, or
biliary disorder
• Subjects with vascular condition which interferes with ambulation
• Known allergy or sensitivity to herbal products, soy or eggs
• Vegetarian or Vegan
• History or presence of cancer in the prior two years, except for non-
melanoma skin cancer.
• Individual has a condition the Investigator believes would interfere
with his or her ability to provide informed consent, comply with the
study protocol, which might confound the interpretation of the study
results or put the person at undue risk
Table 1 Inclusion–exclusion criteria (Continued)
• Untreated or unstable hypothyroidism, an active eating disorder, or
evidence of any neurological disorders
• Recent history of (within 12 months) or strong potential for alcohol
or substance abuse
• Females who are pregnant, lactating, or unwilling to use adequate
contraception during the study
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Knee extension was measured by goniometry. Briefly,
subjects were instructed to sit in an upright position on
a table edge with their backs straight (knee position de-
fined as 90°). The axis of a goniometer was placed at the
intersection of the thigh and shank at the knee joint.
Subjects were asked to bring their knees to full exten-
sion without changing the position of the pelvis and
lumbar spine. The extended knee joint angle was mea-
sured and recorded. For knee flexion measurement, sub-
jects were asked to actively flex their knees while lying
in a prone position with their shins off the end of the
table. The range of knee flexion motion was then mea-
sured and documented.
Timed joint discomfort measurements
Briefly, a stopwatch was started when subjects began
climbing the stepmill. Time to onset of pain was
recorded at the first sign of pain in the target knee. The
baselines at each time point were normalized to account
for dropouts. Percent change in time to complete recov-
ery from pain was measured as follows: a new stopwatch
was started when the subjects disembarked from the
stepmill and the time to complete recovery from pain
was recorded. The baselines at each time point were
normalized to account for dropouts then compared
against the reference interval which was defined as the
percentage change between the study baseline and day 7.
KOOS knee survey & Stanford exercise scales
The KOOS survey is a validated instrument consisting
of 42 questions that are classified into sub-scales such as
symptoms, stiffness, pain, daily activities, recreational ac-
tivities and quality of life [34]. It measures the subjects’
opinion about their knees and their ability to perform
daily activities during the past week. The Stanford exer-
cise behavior scale comprises 6 questions designed to as-
sess exercise behaviors during the previous week [35].
Six minute timed walk
Subjects were instructed to walk up and down a hallway
for 6 minutes as rapidly as possible without causing any
pain. A measuring wheel (RoadRunner Wheel, Keson In-
dustries, Aurora, IL) was used to measure distance trav-
elled in 6 minutes.
Table 2 Protocol summary
Protocol activities V1 V2 V3 V4 V5 V6 V7












Medical history and physical exam x
Vital signs/anthropometric measures x x x x x x x
Urine pregnancy test x x
Administer and review scales/questionnaires/diaries x x x x x x x
Stressor (Udani Stepmill protocol) x x x x x x x
Functional measures (6-min timed walk) x x x x x x x
Goniometry (range of motion) x x x x x x
Review concomitant therapies x x x x x x x
Intercurrent medical issues review x x x x x x
Compliance assessment (including phone calls) x x x x x x
Randomization x
Study supplement preparation & dispensing x x x x x
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No rescue medications were allowed during the course
of the study. At all study visits, subjects were given a list
of the 43 prohibited medications and supplements
(Table 3). Changes in overall medication history, or the
use of these substances, were then recorded by the study
coordinator. Subjects found to have used any of theseFigure 1 Sequence of study procedures at a typical clinic visit.prohibited substances were excluded from further par-
ticipation in the study as per protocol.
Statistics
Outcome variables were assessed for conformance to the
normal distribution and transformed as required. Within
group significance was analyzed by non-parametric Sign








































*Selected from a list of 43 prohibited medications and supplements.
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while Wilcoxon Mann–Whitney test was used to analyze
between groups significance. The Fisher Exact test was
used to evaluate the complete loss of pain between study
cohorts whereas the binomial test was used to assess the
likelihood of complete loss of pain at each visit. P-values
equal to or less than 0.05 were considered statistically
significant. All analyses were done on a per protocolbasis using SPSS, v19 (IBM, Armonk, NY). Results were
presented as mean ± SEM.
Results
Baseline demographics
A total of 55 individuals met the eligibility criteria and
were randomized to the placebo (n = 28) or to the UC-II
(n = 27) group. Baseline demographic characteristics for
subjects in both groups were similar with respect to age,
gender, height, weight and BMI (Table 4). A total of nine
subjects, three in UC-II group and six in placebo group,
were lost to follow-up. The results presented herein en-
compass 46 total subjects, 22 subjects in the placebo
group plus 24 subjects in the UC-II group. It should be
noted that the average age of the study participants was
approximately 46 years which is about 16 years younger
than the average age observed in many OA studies
[36-38].
Knee extension and flexion
Figure 2 summarizes the average knee extension changes
over time for subjects supplemented with either UC-II
or placebo. The UC-II supplemented cohort presented
with a statistically significant greater increase in the abil-
ity to extend the knee at day 120 as compared to the
placebo group (81.0 ± 1.3º vs 74.0 ± 2.2º, p = 0.011) and
to baseline (81.0 ± 1.3º vs 73.2 ± 1.9º, p = 0.002). The UC-
II group also demonstrated a significant increase in knee
extension at day 90 (78.8 ± 1.9º vs 73.2 ± 1.9º, p = 0.045)
compared to baseline only. An intent to treat (ITT) ana-
lysis of these data also demonstrated a statistically sig-
nificant net increase in knee extension at day 120 versus
placebo (80.0 ± 1.3º vs 73.7 ± 1.8º, p = 0.006). No statisti-
cally significant changes were observed in the placebo
group at any time during this study. With respect to
knee flexion, no significant changes were noted in either
study group (p > 0.05). The power associated with the
former per protocol statistical analyses was 80%.
Time to onset of initial joint pain
Supplementation with UC-II resulted in statistically sig-
nificant increases in the time to onset of initial joint pain
at day 90 (2.75 ± 0.5 min, p = 0.041) and at day 120 (2.8
± 0.5 min, p = 0.019) versus a baseline of 1.4 min for
each visit. No statistically significant differences were
noted for either the placebo group or between groups
(Figure 3).
Five individuals in the UC-II group and one in the pla-
cebo group reported no onset of pain by the end of
study (see below and Table 5). Given this unexpected
finding, an additional analysis was undertaken which in-
cluded these individuals in the time to onset of initial
pain analysis. The 10 minute limit of the stepmill pro-
cedure was used as the lower limit to pain onset. Under
Table 4 Demographic and baseline characteristics of
enrolled subjects
Characteristics UC-II Placebo
Total number of subjects 27 28
Number of males 11 12
Number of females 16 16
Age (years) 46.1 ± 1.5 46.6 ± 1.8
Weight (kg) 75.5 ± 2.9 77.5 ± 3.1
Height (cm) 167.1 ± 2.0 168.4 ± 2.0
BMI (kg/m2) 26.8 ± 0.8 27.1 ± 0.7
Values are expressed as Mean ± SEM.
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UC-II yielded statistically significant increases in time to
onset of pain at day 90 (3.65 ± 0.7 min, p = 0.011) and
day 120 (4.31 ± 0.7 min, p = 0.002) versus a baseline of
1.4 min for each visit. The between-group comparison at
day 120 approached the statistical level of significance
favoring the UC-II cohort (p = 0.051).Time to onset of maximum joint pain
A statistically significant difference between groups was
noted at day 60 (6.39 ± 0.5 min vs 4.78 ± 0.5 min;
p = 0.025) favoring the UC-II cohort. This significance
did not persist during the remainder of the study
suggesting that this was a random occurrence.Time to initial improvement in knee joint pain
The time to offset of joint pain was recorded immedi-
ately upon the subject stepping off the stepmill. Both
groups began to recover from pain with the same rate
resulting in no significant differences between groups in
the time to initial offset of joint pain (p > 0.05).Time to complete recovery from knee joint pain
The time to complete recovery from joint pain showed
significant reductions at days 60, 90 and 120 compared
to baseline for both the UC-II group as well as the pla-
cebo group (Figure 4). Percent changes in times were
calculated after normalizing the baselines against the ref-
erence range of baseline to day 7. The UC-II group
exhibited average reductions of 31.9 ± 11.7% (p = 0.041),
51.1 ± 6.1% (p = 0.004) and 51.9 ± 6.0% (p = 0.011) at
days 60, 90 and 120, respectively. By contrast, the reduc-
tions for the same time points for the placebo cohort,
21.9 ± 10.2% (p = 0.017), 22.2 ± 15.5% (p = 0.007) and
30.0 ± 11.8% (p = 0.012), were of lower magnitude but
nonetheless statistically significant versus baseline. None
of these between group differences achieved statistical
significance.Time to complete loss of knee joint pain
During the course of this study it was noted that a num-
ber of subjects in both the placebo and the
supplemented cohorts no longer reported any pain dur-
ing the stepmill protocol. For the UC-II group, 5 sub-
jects (21%) no longer reported pain by day 120, whereas
only 1 subject (5%) in placebo group reported complete
loss of pain (Table 5). This effect did not reach statistical
significance between groups but there was an evident
trend in the data towards a greater number of subjects
losing pain in the UC-II cohort (p = 0.126). A binomial
analysis for complete loss of pain at each visit demon-
strated a statistical significance for the UC-II group by
day 120 (p = 0.031). It is important to note that the
complete loss of knee pain was not a random event. The
pattern among the subjects indicates that loss of knee
pain appeared to be a persistent phenomenon that
spanned multiple visits (Table 5). A detailed review of
the clinical report forms showed that none of these indi-
viduals consumed pain relief medication prior to their
visits.
Six-minute timed walk & Daily number of steps
No significant differences were observed between the
study groups for the six-minute time walk or the daily
number of steps taken (p > 0.05). The distance walked in
six-minutes by the UC-II (range = 505 to 522 meters)
and the placebo (range = 461 to 502 meters) groups were
within the reference range previously reported [39] for
healthy adults (399 to 778 meters, males; 310 to 664 me-
ters, females). Similarly, the average step length calcu-
lated from Fitbit data for both study groups (0.69 to 0.71
meters) also agreed with previously published results for
normal adults [40].
KOOS knee survey & Stanford exercise scales
No significant differences were seen between the study
groups for either the KOOS survey or the Stanford exer-
cise scale (p > 0.05).
Use of analgesics and NSAIDs
Review of the clinical report forms showed that no sub-
ject in either study cohort consumed any of the 43
prohibited medicines or supplements during the study.
Safety assessments
A total of eight adverse events, equally dispersed be-
tween both groups, were noted (Table 6). None of the
adverse events was considered to be associated with UC-
II supplementation. All events resolved spontaneously
without the need for further intervention. No subject
withdrew from the study due to an adverse event. Fi-
nally, no differences were observed in vital signs after
Figure 2 Knee extension as measured by goniometry. Values are presented as Mean ± SEM. *p≤ 0.05 indicates a statistically significant
difference versus baseline or placebo. Number of completers: n = 24 in UC-II group (n = 3 dropouts); n = 20 in placebo group (n = 6 dropouts;
n = 2 did not participate in ROM assessment).
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verse events were reported in this study.
Discussion
In this study, the UC-II supplement, consisting of
undenatured type II collagen, was investigated for its
ability to improve joint function in healthy subjects who
develop joint pain while undergoing strenuous exercise.
The rationale behind this approach centered on the hy-
pothesis that strenuous exercise might uncover transientFigure 3 Impact of stepmill procedure on the onset of pain. Values are
difference from baseline. Number of completers: n = 19 in UC-II group (n =
(n = 6 dropouts; n = 1 did not have pain; n = 1 did not use stepmill).joint changes due to daily physical activities that are not
attributable to a diagnosable disease. In the same way
that nominally elevated blood levels of lipids, glucose
plus high blood pressure and obesity can be predictive
of future progression to diabetes and heart disease [41],
the development of joint pain upon strenuous exercise
may be indicative of possible future joint problems.
At study conclusion, we found that subjects ingesting
the UC-II supplement experienced a significantly greater
forward ROM in their knees versus baseline and placebopresented as Mean ± SEM. *p≤ 0.05 indicates a statistically significant
3 dropouts; n = 5 did not have pain); n = 20 in placebo group
Table 5 Subjects reporting complete loss of knee pain on stepmill test
Visit
UC-II Placebo












Baseline 0.0 (0) 0 NA 0.0 (0) 0 NA
Day 7 0.0 (0) 0 NA 0.0 (0) 0 NA
Day 30 1.0 (4) 1N 0.5 0.0 (0) 0 NA
Day 60 3.0 (13) 1R, 2N 0.125 0.0 (0) 0 NA
Day 90 3.0 (13) 2R, 1N 0.125 1 (5) 1N 0.5
Day 120 5.0 (21) 3R, 2N 0.031† 1 (5) 1R 0.5
Values denote number of subjects while parenthesis provides the percent of total subjects who did not have any pain on stepmill. Continuity indicates the
number of subjects in whom the absence of pain was maintained across visits. †Significant at p ≤ 0.05 based on independent binomial testing of each visit using
the null hypothesis that the probability of a subject experiencing no joint pain is equal to zero. There was no statistical difference between groups. #R Repeat
subject (i.e. same subject who reported no pain in previous visit), N New subject who reports no pain for the first time.
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sion is necessary for daily function and sport activities.
Loss of knee extension has been shown to negatively im-
pact the function of the lower extremity [42,43]. For ex-
ample, loss of knee extension can cause altered gait
patterns affecting ankles and the hip which could result
in difficulty with running and jumping [42,43]. Studies
have further shown that a permanent loss of 3-5º of ex-
tension can significantly impact patient satisfaction and
the development of early arthritis [44].
By contrast, when knee flexion, another measure of knee
function, was assessed via goniometry, no differences in
clinical outcomes were observed between the two study co-
horts. From a structure-function perspective this outcome
is not surprising. During the earliest characterized phasesFigure 4 Percent change in time to complete recovery from pain. Valu
significant difference from baseline. Number of completers: n = 18 in UC-II
recovery from pain was not achieved); n = 20 in placebo group (n = 6 dropof OA there is an apparent preferential loss of knee exten-
sion over knee flexion, and this loss has been shown to cor-
relate with WOMAC pain scores [45,46]. In addition, MRI
imaging of the early osteoarthritic knee has shown that ini-
tial changes in knee structure appear to center on articular
cartilage erosions (fibrillations) about the patella and other
weight bearing regions of the knee [47]. Such changes
might favor a loss in knee ROM that preferentially affects
extension over flexion. The pathophysiology of the early
osteoarthritic knee, we believe, provides insight regarding
the effect of daily physical activities on the healthy knee in-
sofar as it helps explain the discordance in clinical out-
comes between knee extension and flexion.
Both the time to onset of initial joint pain as well as
time to full recovery were measured in this study. Fores are presented as Mean ± SEM. *p≤ 0.05 indicates a statistically
group (n = 3 dropouts; n = 5 did not have pain; n = 1 time to complete
outs; n = 1 did not have pain; n = 1 did not use stepmill).
Table 6 Summary of analysis of adverse events (AEs) in
all subjects
Study groups Adverse event Number
of AEs(Body system)
UC-II Upper respiratory infection (Pulmonary) 3
Food poisoning (Gastrointestinal) 1
Total number of AEs 4
Total number of subjects reporting AEs: n 4/27
Placebo Bilateral ankle edema (Musculoskeletal) 1
Right ankle fracture (Musculoskeletal) 1
Sinusitis (Ears/Nose/Throat) 1
Skin infection right ankle
(Dermatological)
1
Total number of AEs 4
Total number of subjects reporting AEs: n 2/28
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UC-II supplemented cohort versus their baseline status.
The ability of UC-II to modulate knee extension may re-
late to its ability to moderate knee joint pain. Crowley
et al. [26] and Trentham et al. [25] demonstrated that
UC-II effectively enhances joint comfort and flexibility
thereby improving the quality of life (QoL) in both OA
and RA subjects, respectively. This effect may be attrib-
utable to the finding that microgram quantities of
undenatured type II collagen moderate CIA in both the
rat and the mouse via the induction of T regulator cells
[27,28,48]. The induction of these T regulators takes
place within gut associated lymphatic tissues (GALT), in-
cluding mesenteric lymph nodes, in response to the con-
sumption of undenatured type II collagen [27]. Studies
have shown that these regulatory cells produce IL-10
and TGF-β [30,49]. A special class of CD103+ dendritic
cells, found almost exclusively in the GALT, facilitates
this process [48,50]. Once activated, T regulator cells ap-
pear to downregulate a wide range of immunologic and
proinflammatory activities resulting in the moderation of
the arthritic response initiated by undenatured type II
collagen [27]. The phenomenon of oral tolerance has
also been demonstrated in humans, and appears to in-
volve a similar set of T regulators [30,51-53].
The above description of how UC-II might modulate
joint function is most easily understood in the context of
RA given that the CIA animal model resembles this disease
most closely [27,28,54]. However, the case for T regulators
and immune cytokines having a moderating effect on
healthy or OA knee joint function appears less apparent.
This view has changed in recent years due to a growing
body of evidence suggesting that both OA and normal
chondrocyte biology appears to be regulated by some of the
same cytokines and chemokines that regulate inflammation
[5,6,55]. For example, Mannelli and coworkers [56] recentlyreported that feeding microgram amounts of native type II
collagen (porcine) prevents monoiodoacetate-induced ar-
ticular cartilage damage in this rat model of osteoarthritis,
as measured by pain thresholds and by circulating levels of
cross linked c-telopeptides derived from type II collagen.
This finding corroborates the efficacy of undenatured type
II collagen in improving joint comfort in osteoarthritic con-
ditions [26].
In the present study, we show for the first time that
UC-II can improve joint function in healthy subjects
undergoing strenuous physical exercise. This observa-
tion, when considered in context with normal chondro-
cyte physiology, suggests that activated T regulator cells,
specific for undenatured type II collagen, home to an
overstressed knee joint where their release of the anti-
inflammatory cytokines, IL-10 and TGF-β reverse the
catabolic changes caused by strenuous exertion
[13,21,57]. In addition, the IL-10 and TGF-β produced
by these T regulators may tilt the TH balance in the knee
joint towards TH2 [30,58] responses which preferentially
result in IL-4 production further fostering a shift in
chondrocyte metabolism towards ECM replenishment.
Several additional tests were used in this study to as-
sess overall joint function, QoL, and physical activity.
The additional parameters and tests measured included
a six minute timed walk plus the Stanford exercise scale
and KOOS survey. With respect to the KOOS survey,
both cohorts were statistically significant versus baseline
for symptoms, pain, daily function, recreational activities
and QoL but were not significant from each other. This
is not an unexpected finding given that this study was
carried out with healthy subjects who do not present
with any joint issues at rest. It is only when the knee is
stressed via the stepmill do subjects report any joint dis-
comfort. Under these conditions, and as indicated above,
the UC-II group appears to experience less joint discom-
fort and greater joint flexibility. No difference in clinical
outcomes between groups was seen in the six minute
timed walk, the daily distance walked, or the Stanford
exercise scale questionnaire. Once again we are not sur-
prised by these results given that these tests and ques-
tionnaires are designed and clinically validated to assess
the severity of arthritic disease in unhealthy populations.
No clinical biomarkers associated with arthritic dis-
eases were assessed in this study. Healthy subjects would
not be expected to present with significant alterations in
their inflammatory biomarker profile as they lack clinical
disease [59]. In addition, it should be noted that the joint
discomfort measured in this study is acute pain induced
by a stressor rather than due to an ongoing inflamma-
tory event. Therefore, any elevation in inflammation
markers that might occur in these healthy subjects may
simply be due to the physiological impact of strenuous
exercise.
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http://www.jissn.com/content/10/1/48There are two study limitations to consider when
reviewing these results. The first, time to onset of initial
pain, was limited to a 10-minute interval. The current study
design did not address the possibility that subjects might
cease to experience pain on the stepmill. Future studies
should allow for an extension of the exertion interval in
order to gauge how much longer a subject can exercise be-
fore reporting pain. In this way better defined parameters
can be placed upon the degree to which UC-II supplemen-
tation results in the cessation of joint pain due to strenuous
exercise in healthy subjects.
The second limitation that merits consideration is the
possibility that study subjects may have early signs of arth-
ritis that do not meet the ACR criteria. This possible limita-
tion was addressed by performing an extensive medical
examination for signs and symptoms of OA and by exclu-
ding volunteers who experienced pain levels of 5 or greater
within one minute of using the stepmill.
UC-II is a unique ingredient that supports healthy joints.
Previous studies have focused on the efficacy of this ingre-
dient in OA subjects. By including healthy subjects in this
study, and using non-disease endpoints as a measure of effi-
cacy, it is believed that the benefits that derive from UC-II
usage now extends to include healthy individuals. Further,
this ingredient appears to be safe for human consumption
based on an extensive series of in vivo and in vitro toxico-
logical studies as well as the absence of any adverse events
in this and in previous human studies [24,26,60]. In conclu-
sion, daily supplementation with 40 mg of UC-II supports
joint function and flexibility in healthy subjects as demon-
strated by greater knee extension and has the potential both
to alleviate the joint pain that occasionally arises from
strenuous exercise as well as to lengthen periods of pain
free exertion.
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